FDA Clears New AI-Powered Spine MRI Software
Trained on over five million spine MRI scans, the RAI software reportedly facilitates rapid pathology detection and enhanced consistency with disc measurement.
The Food and Drug Administration (FDA) has granted 510(k) clearance for RAI, an artificial intelligence (AI)-enabled software for spine magnetic resonance imaging (MRI) that may foster improved detection of abnormal findings and degenerative pathology.
Currently utilized by over 300 radiologists worldwide, the RAI software (Remedy Logic) offers automated segmentation and disc measurements that may reduce reading time for radiologists. The software also flags incidental findings, identifies abnormalities, and provides concise summaries for pathology detection, according to Remedy Logic.
Currently utilized by over 300 radiologists worldwide, RAI, the newly FDA-cleared AI software for spine MRI, reportedly offers automated segmentation and disc measurements that may reduce reading time for radiologists, according to Remedy Logic, the developer of RAI. (Images courtesy of Remedy Logic.)
The company noted that RAI, which will be showcased at the upcoming Radiological Society of North American (RSNA) 2004 Annual Meeting in Chicago, has been trained with over five million spine MRI scans.
“This achievement (FDA clearance) underscores our commitment to improving efficiency for radiologists for improved safety for patients and completeness and objectivity for referring physicians. who have been left behind by innovation, while addressing the critical issue of spine MRI volumes outpacing available radiologists,” noted Andrej Rusakov, the CEO of Remedy Logic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Ultrafast MRI Enhance Detection of Malignant Foci for Breast Cancer?
April 10th 2025In a new study involving over 120 women, nearly two-thirds of whom had a family history of breast cancer, ultrafast MRI findings revealed a 5 percent increase in malignancy risk for each second increase in the difference between lesion and background parenchymal enhancement (BPE) time to enhancement (TTE).
AMA Approves Category III CPT Codes for AI-Enabled Perivascular Fat Analysis from CT Scans
April 9th 2025Going into effect in 2026, the new CPT codes may facilitate increased adoption of the CaRi-Heart software for detecting coronary inflammation from computed tomography scans pending FDA clearance of the technology.
